This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
This non-interventional long-term follow-up study will involve one telephonic contact in all 1800 former participants from study ACYWX-03 followed by one visit beyond five years after vaccination in a subset of 450 participants. This subset will be randomly selected to participate in a follow-on immune persistence evaluation. To document the duration of the immune response and any requirement of booster dose in the target population, this study is intended to explore antibody persistence.
Study Type
OBSERVATIONAL
Enrollment
450
Geometric mean titers (GMTs) measured by rSBA against serogroups A, C, Y, W and X
Time frame: five-six years after vaccination.
Percentage of participants with rSBA titers ≥ 8
Time frame: five-six years after vaccination.
Percentage of participants with rSBA titers ≥ 128
Time frame: five-six years after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.